Buscar

01/12/2022 Long-term follow-up of certolizumab pegol in uveitis due to immune-mediated inflammatory diseases: multicentre study of 80 patients
Martin-Varillas, JL, Sanchez-Bilbao, L, Calvo-Rio, V, Adan, A, Hernanz, I, Gallego-Flores, A, Beltran-Catalan, E, Castro-Oreiro, S, Fanlo, P, Martos, AG, Torre, I, Cordero-Coma, M, De Dios, JR, Garcia-Aparicio, A, Hernandez-Garfella, M, Sanchez-Andrade, A, Garcia-Valle, A, Maiz, O, Miguelez, R, Rodriguez-Montero, S, Urruticoechea, A, Veroz, R, Conesa, A, Fernandez-Carballido, C, Jovani, V, Mondejar, JJ, Gonzalez, OM, Alvarado, PM, Romero-Yuste, S, Rubio-Munoz, P, Pena-Sainz-Pardo, E, Garijo-Bufort, M, Demetrio-Pablo, R, Hernandez, JL, Blanco, R. Long-term follow-up of certolizumab pegol in uveitis due to immune-mediated inflammatory diseases: multicentre study of 80 patients. RMD Open. 2022; 8(2)DOI:10.1136/rmdopen-2022-002693. PMID:36597972. IF:6.200(Q1/2D).
17/10/2022 Not all autoantibodies are clinically relevant. Classic and novel autoantibodies in Sjogren's syndrome: A critical review
Vilchez-Oya, F, Martin, HB, Garcia-Martinez, E, Corominas, H. Not all autoantibodies are clinically relevant. Classic and novel autoantibodies in Sjogren's syndrome: A critical review. Frontiers in Immunology. 2022; 13DOI:10.3389/fimmu.2022.1003054. PMID:36325321. IF:7.300(Q1/3D).
01/08/2022 Subclinical giant cell arteritis in new onset polymyalgia rheumatica A systematic review and meta-analysis of individual patient data
Hemmig, AK, Gozzoli, D, Werlen, L, Ewald, H, Aschwanden, M, Blockmans, D, Brouwer, E, Buchanan, RRC, Camellino, D, Campochiaro, C, Cimmino, MA, Corominas, H, Gloy, V, Henckaerts, L, Kyburz, D, Moya-Alvarado, P, Owen, CE, Stegert, M, Tomelleri, A, van Sleen, Y, Yamashita, H, Imfeld, S, Berger, CT, Hemkens, LG, Daikeler, T. Subclinical giant cell arteritis in new onset polymyalgia rheumatica A systematic review and meta-analysis of individual patient data. SEMINARS IN ARTHRITIS AND RHEUMATISM. 2022; 55DOI:10.1016/j.semarthrit.2022.152017. PMID:35537222. IF:5.000(Q2/3D).
01/08/2022 A multi-criteria decision analysis on the value of nintedanib for interstitial lung diseases
Zozaya N., Arrizubieta Basterrechea M.I., Bollo E., Castellví I., Espín J., Ortego N., Poveda-Andrés J.L., Rodríguez Portal J.A., Rivero A., Marcos-Rodríguez J.A., Verde L.. A multi-criteria decision analysis on the value of nintedanib for interstitial lung diseases. INTERNATIONAL JOURNAL OF TECHNOLOGY ASSESSMENT IN HEALTH CARE. 2022; 38(1)DOI:10.1017/S0266462322000459. PMID:35912833. IF:3.200(Q2/5D).